Kroeger Christopher A. 4

What Happened

• Christopher A. Kroeger, CEO of MapLight Therapeutics (MPLT), was granted two equity awards on 2026-02-05 totaling 117,100 units: 23,145 shares and 93,955 derivative RSUs. Both grants show an acquisition price of $0.00 (awards, not purchases), so there was no cash paid.
• The 93,955 units are derivative RSUs (contingent rights to receive common stock upon vesting). These awards do not represent an immediate sale or open-market purchase.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (timely within the 2-business-day rule).
• Price: $0.00 for both entries (award/grant).
• Total units granted: 117,100 (23,145 + 93,955).
• Shares owned after the transaction: not specified in this filing.
• Vesting notes from the filing:
  • One RSU award: 1/4 vests on Jan 1, 2027, then 1/16th vests each subsequent April 1, July 1, Oct 1 and Jan 1, subject to continued service.
  • Another award/option-style grant: 1/4 vests on Feb 5, 2027, then 1/48th vests each month thereafter, subject to continued service.
  • Each RSU represents a contingent right to receive one share of common stock.
• Trust holding: some shares are held by the C&M Kroeger Nominee Trust; the CEO is co‑trustee and has voting and dispositive power.

Context

• RSUs are compensation awards that convert to actual shares only as they vest; they involve no immediate cash outlay or market sale. Such grants are common executive compensation and do not, by themselves, indicate a buy or sell signal.
• The filing appears timely. For retail investors, note the staggered vesting means any eventual increase in beneficial ownership and potential insider sales (if any) would occur over time as units vest.